Rochester, MN - Starting a 72-hour infusion of nesiritide (Natrecor, Scios/Johnson & Johnson) after successful MI reperfusion therapy apparently suppressed aldosterone levels and may have had a ...

The drug met primary safety and efficacy outcomes, with full results to be presented at the AHA Scientific Sessions.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight ...

When reading the ECG of a patient presenting with cardiopulmonary complaints, the most important duty of acute care clinicians is to determine whether there is evidence of an acute coronary occlusion ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...

“Beta blockers were developed at a time before routine reperfusion therapy for acute heart attacks and the evolution of more potent medications, and care has really evolved,” said Fonarow. Pfau said ...

Alternative model systems to study ischemia-reperfusion are needed to support a wide range of disease-related investigations in the life sciences. Ischemia and reperfusion are relevant to many disease ...

Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when blood flow is restored following a stroke. As many as one in four people ...